Selected article for: "binding site and display library"
Author: Singh, Sudhakar; Dahiya, Surbhi; Singh, Yuviana J.; Beeton, Komal; Jain, Ayush; Sarkar, Roman; Dubey, Abhishek; Tehseen, Syed Azeez; Sehrawat, Sharvan
Title: Targeting conserved viral virulence determinants by single domain antibodies to block SARS-CoV2 infectivity
  • Cord-id: zdh8gc27
  • Document date: 2021_1_13
    • ID: zdh8gc27
    Snippet: We selected SARS-CoV2 specific single domain antibodies (sdAbs) from a previously constructed phage display library using synthetic immunogenic peptides of the virus spike (S) protein as bait. The sdAbs targeting the cleavage site (CS) and the receptor binding domain (RBD) in S protein efficiently neutralised the infectivity of a pseudovirus expressing SARS-CoV2 S protein. Anti-CS sdAb blocked the virus infectivity by inhibiting proteolytic processing of SARS-CoV2 S protein. Both the sdAbs retai
    Document: We selected SARS-CoV2 specific single domain antibodies (sdAbs) from a previously constructed phage display library using synthetic immunogenic peptides of the virus spike (S) protein as bait. The sdAbs targeting the cleavage site (CS) and the receptor binding domain (RBD) in S protein efficiently neutralised the infectivity of a pseudovirus expressing SARS-CoV2 S protein. Anti-CS sdAb blocked the virus infectivity by inhibiting proteolytic processing of SARS-CoV2 S protein. Both the sdAbs retained characteristic structure within the pH range of 2 to 12 and remained stable upto 65°C. Furthermore, structural disruptions induced by a high temperature in both the sdAbs were largely reversed upon their gradual cooling and the resulting products neutralised the reporter virus. Our results therefore suggest that targeting CS in addition to the RBD of S protein by sdAbs could serve as a viable option to reduce SARS-CoV2 infectivity and that proteolytic processing of the viral S protein is critical for infection.

    Search related documents:
    Co phrase search for related documents
    • absence presence and acute respiratory: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25
    • absence presence and additional experiment: 1, 2
    • absence presence and ade antibody dependent enhancement: 1, 2
    • absence presence and low abundance: 1, 2
    • absence presence and low concentration: 1, 2, 3
    • absence presence and low temperature: 1, 2, 3
    • absence presence and lysis buffer: 1, 2, 3, 4, 5
    • acute respiratory and ade antibody dependent enhancement: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25
    • acute respiratory and low abundance: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11
    • acute respiratory and low concentration: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25
    • acute respiratory and low temperature: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25
    • acute respiratory and lysis buffer: 1, 2, 3, 4, 5, 6, 7
    • ade antibody dependent enhancement and low concentration: 1
    • low concentration and lysis buffer: 1, 2